Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Torametinib + vemurafenib in BRAF-mutant relapsed/refractory Langerhans cell histiocytosis
ChiCTR2500104645Phase 2Recruiting
- Sponsor
- Shanghai Sixth People's Hospital
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trametinib and vemurafenib in Langerhans cell histiocytosis (LCH), sponsored by Shanghai Sixth People's Hospital. Primary endpoints: Objective response rate, Determine the recommended dose for adolescent subjects in Phase II and 1 more. Started Jun 2025; status: recruiting.
02
Drugs
trametinibvemurafenib
03
Conditions
Langerhans cell histiocytosis (LCH)
Beyond the preview
Go deeper on ChiCTR2500104645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500104645.